STOXIL
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Apr 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STOXIL is an ophthalmic solution (eye drops) approved by GSK in 1964 for viral eye infections. The specific mechanism of action and therapeutic class are not currently documented, but the formulation indicates topical antiviral or anti-inflammatory activity. This is a legacy small-molecule product with decades of clinical use.
LOE Approaching
Product faces moderate competitive pressure (30/100) in ophthalmology with minimal current job openings, indicating a mature brand with limited expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STOXIL currently shows zero linked job openings, indicating a mature product with a stable, small team structure. Career opportunities are limited to niche roles in brand management and field execution rather than growth-phase expansion.
Brand ManagerRegional Sales Manager
Worked on STOXIL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.